Phaseline

Companies › Kartos Therapeutics

Kartos Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Navtemadlin (KRT-232)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 3Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03669965Navtemadlin (KRT-232)Phase 2Polycythemia VeraOncologyApr 2022
NCT04502394Navtemadlin (KRT-232)Phase 1Diffuse Large B Cell LymphomaOncologyOct 2022
NCT06479135Navtemadlin (KRT-232)Phase 3MyelofibrosisOncologyDec 2026
NCT04190550Navtemadlin (KRT-232)Phase 1Acute Myeloid LeukemiaOncologyJun 2027
NCT03041688Navtemadlin (KRT-232)Phase 1Acute Myeloid LeukemiaOncologyJun 2027
NCT05797831Navtemadlin (KRT-232)Phase 2Endometrial CancerOncologyJul 2027

Targets

TP53 (1) MDM2 (1)

Companies with the same targets

SynerGene Therapeutics PMV Pharmaceuticals Precigen OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Nutshell Therapeutics (Shanghai) Jacobio Pharmaceuticals Clasp Therapeutics Ascentage Pharma Group Boehringer Ingelheim

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.